FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects

F-box and WD repeat domain-containing 7 (FBXW7), formerly known as hCdc4, hAGO Fbw7, or SEL10, plays a specific recognition function in SCF-type E3 ubiquitin ligases. FBXW7 is a well-established cancer suppressor gene that specifically controls proteasomal degradation and destruction of many key onc...

Full description

Saved in:
Bibliographic Details
Main Authors: Wanqing Wang, Xue Liu, Lingling Zhao, Kaipeng Jiang, Ziyi Yu, Ruihan Yang, Wenshuo Zhou, Jiuwei Cui, Tingting Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1505027/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850250584251170816
author Wanqing Wang
Xue Liu
Lingling Zhao
Kaipeng Jiang
Ziyi Yu
Ruihan Yang
Wenshuo Zhou
Jiuwei Cui
Tingting Liang
author_facet Wanqing Wang
Xue Liu
Lingling Zhao
Kaipeng Jiang
Ziyi Yu
Ruihan Yang
Wenshuo Zhou
Jiuwei Cui
Tingting Liang
author_sort Wanqing Wang
collection DOAJ
description F-box and WD repeat domain-containing 7 (FBXW7), formerly known as hCdc4, hAGO Fbw7, or SEL10, plays a specific recognition function in SCF-type E3 ubiquitin ligases. FBXW7 is a well-established cancer suppressor gene that specifically controls proteasomal degradation and destruction of many key oncogenic substrates. The FBXW7 gene is frequently abnormal in human malignancies especially in gastrointestinal cancers. Accumulating evidence reveals that mutations and deletions of FBXW7 are participating in the occurrence, progression and treatment resistance of human gastrointestinal cancers. Considering the current therapeutic challenges faced by gastrointestinal cancers, elucidating the biological function and molecular mechanism of FBXW7 can provide new perspectives and references for future personalized treatment strategies. In this review, we elucidate the key molecular mechanisms by which FBXW7 and its substrates are involved in gastrointestinal cancers. Furthermore, we discuss the consequences of FBXW7 loss or dysfunction in tumor progression and underscore its potential as a prognostic and therapeutic biomarker. Lastly, we propose potential therapeutic strategies targeting FBXW7 to guide the precision treatment of gastrointestinal cancers.
format Article
id doaj-art-e61f97fb07bd4b1d9edc7228efbc99e3
institution OA Journals
issn 1663-9812
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-e61f97fb07bd4b1d9edc7228efbc99e32025-08-20T01:58:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.15050271505027FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospectsWanqing WangXue LiuLingling ZhaoKaipeng JiangZiyi YuRuihan YangWenshuo ZhouJiuwei CuiTingting LiangF-box and WD repeat domain-containing 7 (FBXW7), formerly known as hCdc4, hAGO Fbw7, or SEL10, plays a specific recognition function in SCF-type E3 ubiquitin ligases. FBXW7 is a well-established cancer suppressor gene that specifically controls proteasomal degradation and destruction of many key oncogenic substrates. The FBXW7 gene is frequently abnormal in human malignancies especially in gastrointestinal cancers. Accumulating evidence reveals that mutations and deletions of FBXW7 are participating in the occurrence, progression and treatment resistance of human gastrointestinal cancers. Considering the current therapeutic challenges faced by gastrointestinal cancers, elucidating the biological function and molecular mechanism of FBXW7 can provide new perspectives and references for future personalized treatment strategies. In this review, we elucidate the key molecular mechanisms by which FBXW7 and its substrates are involved in gastrointestinal cancers. Furthermore, we discuss the consequences of FBXW7 loss or dysfunction in tumor progression and underscore its potential as a prognostic and therapeutic biomarker. Lastly, we propose potential therapeutic strategies targeting FBXW7 to guide the precision treatment of gastrointestinal cancers.https://www.frontiersin.org/articles/10.3389/fphar.2024.1505027/fullFBXW7gastrointestinal cancersmolecular mechanismtherapeutic strategiesbiomarker
spellingShingle Wanqing Wang
Xue Liu
Lingling Zhao
Kaipeng Jiang
Ziyi Yu
Ruihan Yang
Wenshuo Zhou
Jiuwei Cui
Tingting Liang
FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
Frontiers in Pharmacology
FBXW7
gastrointestinal cancers
molecular mechanism
therapeutic strategies
biomarker
title FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
title_full FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
title_fullStr FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
title_full_unstemmed FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
title_short FBXW7 in gastrointestinal cancers: from molecular mechanisms to therapeutic prospects
title_sort fbxw7 in gastrointestinal cancers from molecular mechanisms to therapeutic prospects
topic FBXW7
gastrointestinal cancers
molecular mechanism
therapeutic strategies
biomarker
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1505027/full
work_keys_str_mv AT wanqingwang fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT xueliu fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT linglingzhao fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT kaipengjiang fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT ziyiyu fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT ruihanyang fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT wenshuozhou fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT jiuweicui fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects
AT tingtingliang fbxw7ingastrointestinalcancersfrommolecularmechanismstotherapeuticprospects